Share This Author
Treatment of advanced squamous cell carcinoma of the lung: a review.
- B. Derman, K. Mileham, P. Bonomi, M. Batus, M. Fidler
- MedicineTranslational lung cancer research
- 7 July 2015
An expanding role for immunotherapy is confirmed and a potential opportunity for VEGFR inhibition, and even future targets in fibroblast growth factor receptor (FGFR) and PI3K-AKT that collectively should improve survival as well as quality of life for those affected by squamous cell lung cancer over the next decade are confirmed.
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
This phase 2 multicenter study evaluated incorporation of autologous stem cell transplant (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma and met the primary endpoint, with an sCR rate of 60% after 8 cycles.
Bendamustine-induced nephrogenic diabetes insipidus .
- B. Derman, Milli Jain, Elizabeth A. McAninch, Casey N Gashti
- Medicine, BiologyClinical nephrology
It is proposed that bendamustine, similar to the alkylating agent ifosfamide, is toxic to the glomerulus and proximal tubule cells and is the most likely cause of the patient's nephrogenic DI.
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.
A GA-guided MDC for older HCT candidates is feasible and seems to reduce transplant-associated morbidity and mortality, and should encourage broader and safer utilization of transplantation in older patients.
Risk Factors, Diagnosis, Management, and Outcome of Splanchnic Vein Thrombosis: A Retrospective Analysis.
A higher incidence of regional cancer and surgery and a lower incidence of the JAK2 V617F mutation are found in patients diagnosed with splanchnic vein thrombosis.
Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer
High baseline and progressive increases in NLRs are associated with progressive disease, inferior OS and weight loss in NSCLC patients, and these observations suggest that studying molecular mediators of cachexia/inflammation and their relationships to tumor progression may identify new therapeutic targets in the large subset of NSClC patients who have cancer cachexia.
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes.
Cognitive impairment elevates risk of post-alloHCT NRM in older patients, according to a preplanned subgroup analysis in 224 patients aged ≥60 years.
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
An international panel of MM investigators convenes to harmonize how MRD should be assessed and reported in MM clinical trials, and provides guidance regarding the incorporation of newer peripheral blood-based and imaging-based approaches to detection of residual disease.
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell…